Oxaloplatino [Spanish]
Categoria
Oxaloplatino [Spanish] Nombres de marca, Oxaloplatino [Spanish] Analogos
Oxaloplatino [Spanish] Marca los nombres de mezcla
Oxaloplatino [Spanish] Formula quimica
Oxaloplatino [Spanish] RX enlace
Oxaloplatino [Spanish] FDA hoja
Oxaloplatino [Spanish] MSDS (hoja de seguridad de materiales)
Oxaloplatino [Spanish] Sintesis de referencia
Oxaloplatino [Spanish] Peso molecular
Oxaloplatino [Spanish] Punto de fusion
Oxaloplatino [Spanish] H2O Solubilidad
Oxaloplatino [Spanish] Estado
Oxaloplatino [Spanish] LogP
Oxaloplatino [Spanish] Formas de dosificacion
Oxaloplatino [Spanish] Indicacion
Oxaloplatino [Spanish] Farmacologia
Oxaloplatino [Spanish] Absorcion
Oxaloplatino [Spanish] Toxicidad
Oxaloplatino [Spanish] Informacion de Pacientes
Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.
Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.
Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.
![Oxaloplatino_[Spanish]](/images/rx/APRD00186.gif)
